as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 19 Nov 2026
₹1,604.8
Change
-16.5 (-1.02%)
Open
₹1,624.8
Prev. Close
₹1,621.3
Day High
₹1,644.1
Day Low
₹1,584.0
Volume Analysis
Traded
164,369
Delivered
56,569
Delivery %
34.42%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (1)
- •Strong operating margin (27.0%)
Weaknesses (0)
No signal for this stock
Opportunities (2)
- •Strong 3-year EPS growth (59.8%)
- •Strong 3-year revenue growth (15.3%)
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹1,698.04 | ₹1,671.07 | ₹1,637.94 | ₹1,610.97 | ₹1,577.84 | ₹1,550.87 | ₹1,517.74 |
| Fibonacci | ₹1,671.07 | ₹1,648.11 | ₹1,633.93 | ₹1,610.97 | ₹1,588.01 | ₹1,573.83 | ₹1,550.87 |
| Camarilla | ₹1,621.33 | ₹1,615.82 | ₹1,610.31 | ₹1,610.97 | ₹1,599.29 | ₹1,593.78 | ₹1,588.27 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
—
1 Week
-2.29%
1 Month
+32.8%
3 Months
—
6 Months
—
1 Year
—
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹289.0
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
8.17%
Net margin 12.66% × asset turnover 0.43x × equity multiplier 1.5x
Company Overview
Sector
Healthcare
Market Cap
₹10,354 Cr
P/E (TTM)
70.0
ROE
11.7%
Book Value
₹212.0
Face Value
₹2.0
Source: Screener.in (Consolidated figures) — data as of 15 Nov 2026. Not investment advice.
TopFund Analysis
Symbiotec Pharmalab Ltd lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 60/100. The strongest factor is Financial Strength (100/100), while Valuation (2/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (27.0%). Strong 3-year EPS growth (59.8%).
TopFund Score — Fundamentals Quality
60/100 — AverageData confidence: 76/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company has reduced debt.
- −Stock is trading at 7.61 times its book value
- −Though the company is reporting repeated profits, it is not paying out dividend
- −Company has a low return on equity of 12.9% over last 3 years.
- −Company might be capitalizing the interest cost
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Transcript of the Earnings conference call for the Analysts and Investors for the Quarter and Half year ended
Symbiotec will attend Avendus Spark investor conference on 16 November 2026 in Mumbai.
The News Paper advertisement with respect to the unaudited Financial Results of the company for the quarter and half year ended September 30, 2026
Audio recording of analysts’ and investors’ conference call held on November 06, 2026, posted online.
Signed 10-year take-or-pay CDMO deal to manufacture fermentation-based alternative protein for a European innovator.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|
| Sales + | 203 | 196 | 245 | 218 | 280 |
| Expenses + | 145 | 145 | 183 | 173 | 188 |
| Operating Profit | 58 | 50 | 62 | 45 | 92 |
| OPM % | 29.0% | 26.0% | 25.0% | 21.0% | 33.0% |
| Other Income + | 3 | 0 | 0 | 0 | 0 |
| Interest | 5 | 6 | 7 | 6 | 6 |
| Depreciation | 11 | 11 | 20 | 22 | 22 |
| Profit before tax | 45 | 33 | 35 | 18 | 64 |
| Tax % | 33.0% | 43.0% | 22.0% | 20.0% | 19.0% |
| Net Profit + | 30 | 19 | 28 | 14 | 52 |
| EPS in Rs | 47 | 30 | 4 | 2 | 8 |
| Raw PDF | — | — | — | — | — |
| YoY Sales growth | — | — | — | 7 | 43 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Sales + | 633 | 682 | 567 | 716 | 752 | 869 |
| Expenses + | 438 | 550 | 497 | 544 | 549 | 630 |
| Operating Profit | 195 | 131 | 70 | 172 | 203 | 239 |
| OPM % | 31.0% | 19.0% | 12.0% | 24.0% | 27.0% | 27.0% |
| Other Income + | 7 | 3 | 6 | 7 | 4 | -6 |
| Interest | 7 | 3 | 8 | 8 | 17 | 26 |
| Depreciation | 22 | 26 | 29 | 39 | 43 | 53 |
| Profit before tax | 173 | 105 | 39 | 132 | 147 | 153 |
| Tax % | 28.0% | 27.0% | 38.0% | 23.0% | 34.0% | 28.0% |
| Net Profit + | 123 | 78 | 23 | 100 | 97 | 110 |
| EPS in Rs | 23 | 14 | 4 | 18 | 152 | 18 |
| Dividend Payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Sales growth | — | 8 | -17 | 26 | 5 | 16 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|
| Reserves | 510 | 588 | 611 | 704 | 804 | 1,137 | 1,348 |
| Borrowings + | 47 | 65 | 218 | 247 | 544 | 391 | 336 |
| Other Liabilities + | 200 | 152 | 151 | 326 | 220 | 240 | 347 |
| Total Liabilities | 768 | 815 | 990 | 1,289 | 1,580 | 1,781 | 2,044 |
| Fixed Assets + | 261 | 280 | 299 | 448 | 438 | 1,120 | 1,091 |
| CWIP | 28 | 40 | 182 | 208 | 568 | 64 | 138 |
| Investments | 5 | 5 | 5 | 4 | 1 | 4 | 4 |
| Other Assets + | 474 | 490 | 504 | 628 | 572 | 592 | 811 |
| Total Assets | 768 | 815 | 990 | 1,289 | 1,580 | 1,781 | 2,044 |
| Equity Capital | 11 | 11 | 11 | 11 | 11 | 13 | 13 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 174 | 18 | 69 | 188 | 47 | 175 |
| Cash from Investing Activity + | -96 | -32 | -220 | -206 | -307 | -227 |
| Cash from Financing Activity + | -79 | 15 | 146 | 22 | 278 | 36 |
| Net Cash Flow | -1 | 1 | -5 | 3 | 19 | -16 |
| Free Cash Flow | 87 | -55 | -155 | -22 | -261 | -50 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 112 | 36 | 124 | 129 | 40 | 99 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Sep 2026 | |
|---|---|
| Public | 29.77% |
| Promoters | 33.28% |
| FII | 3.79% |
| DII | 33.17% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Symbiotec Pharmalab Ltd (this stock) | 10,354 | 70.0 | 7.6 | 11.7% |
| Yatharth Hosp & Tra C S L | 10,222 | 53.6 | 5.44 | 10.2% |
| Blue Jet Healthcare Ltd | 9,989 | 70.9 | — | 52.1% |
| Park Medi World Limited | 11,039 | 43.1 | 5.12 | 16.8% |
| Jupiter Life Line Hosp L | 9,507 | 50.0 | 5.84 | 13.1% |
| Akums Drugs And Pharma L | 11,279 | 29.9 | 3.22 | 8.45% |
| Viyash Scientific Limited | 11,285 | 46.6 | 3.56 | 7.39% |
Which Mutual Funds Hold Symbiotec Pharmalab Ltd?
Frequently Asked Questions about Symbiotec Pharmalab Ltd
Symbiotec Pharmalab Ltd (SYMBIOTEC) closed at ₹1,604.8 on NSE on 19 November 2026, down 16.5 (1.02%) from the previous close.
Symbiotec Pharmalab Ltd trades on the NSE (National Stock Exchange of India) under the symbol SYMBIOTEC.
Symbiotec Pharmalab Ltd has a trailing twelve-month P/E (price-to-earnings) ratio of 70.0.
Symbiotec Pharmalab Ltd has a dividend yield of 0.0%.
Symbiotec Pharmalab Ltd's 52-week high is ₹1,655.0 and its 52-week low is ₹934.0.
Symbiotec Pharmalab Ltd has a market capitalisation of ₹10,354 crore.
Symbiotec Pharmalab Ltd has a TopFund Quality Score of 60/100 (Average), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Symbiotec Pharmalab Ltd?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.